Source facts
FDA issued an approval letter for NGENLA on 2026-05-01. The source metadata identifies BLA 761184 as a supplement. Review the exact FDA letter for the approved conditions and labeling.
US FDA source recordAL · Approval Letter
NGENLA — FDA Approval Letter (BLA 761184)
Issued to PFIZER IRELAND PHARMACEUTICALS. Application is approved as submitted.
Issued
May 1, 2026Application
BLA • 761184
Product
NGENLA
Company
PFIZER IRELAND PHARMACEUTICALS
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for NGENLA?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
- 1FDA action: approval.
- 2Application: BLA 761184.
- 3Submission: supplement.
- 4Sponsor: PFIZER IRELAND PHARMACEUTICALS.
Suggested next step
Review the exact FDA letter for approved conditions, labeling, and postmarketing requirements.
Open the document workspaceFDA source document
Read the full FDA approval letter (PDF)
Loading document viewer…
Common questions about the NGENLA approval letter
Is NGENLA FDA approved?
This letter documents an FDA approval action: FDA approved BLA 761184 for NGENLA, sponsored by PFIZER IRELAND PHARMACEUTICALS, on May 1, 2026. Product may be marketed. Verify current status and labeling in the source letter, since later FDA actions can change them.
What is BLA 761184?
BLA 761184 is the application under which FDA issued this approval letter for NGENLA to PFIZER IRELAND PHARMACEUTICALS. The letter is dated May 1, 2026.
What happens after an FDA approval letter?
The sponsor may market the product in line with the approved labeling. Approval letters typically set post-approval obligations: submitting final content of labeling, meeting any postmarketing requirements or commitments listed in the letter, updating Orange Book patent information within 30 days for NDAs, and ongoing annual reporting under 21 CFR 314.81.